WIL Research Acquires Ricerca’s Pharma Service Business in Lyon, France - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

WIL Research Acquires Ricerca’s Pharma Service Business in Lyon, France
The move doubles the CRO’s capacity in Europe.


The CRO WIL Research has acquired Ricerca Biosciences’ pharmaceutical services business located in Lyon, France. The addition of the 18,000-m2 facility strengthens WIL Research’s service offerings in Europe, adds to its nonclinical safety assessment capability, and expands its portfolio of specialty services. The acquisition doubles WIL’s capacity in Europe, according to a WIL press release.

Renamed WIL Research Europe–Lyon, the laboratory will retain its approximately 280 employees. Long-time Managing Director of the facility, Stéphane Bulle, will continue to lead the site and keep his current senior leadership team intact, according to the WIL statement.

The Lyon facility provides safety pharmacology and specialized services, including continuous infusion and developmental and reproductive toxicology. WIL Research now has approximately 1200 staff worldwide and 63,000 m2 of laboratory space in the US, The Netherlands, and now Lyon, France. It also maintains commercial representation in Asia.

For Ricerca, the divestiture provides further funding for its Ohio operations. “This divestiture will fund significant capital investment into our Concord, Ohio business allowing us to expand and re-invigorate our integrated drug development services in chemical development, drug substance production, and drug safety and metabolism,” commented Michael Placke, president of Ricerca Biosciences, in the WIL statement.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here